Breaking News, Collaborations & Alliances

Voyager Therapeutics, Novartis Enter Strategic Capsid Collaboration

Novartis obtains target-exclusive access to Voyager’s TRACER capsids related to Huntington’s disease and spinal muscular atrophy.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Voyager Therapeutics, Inc., a biotechnology company advancing neurogenetic medicines, entered a strategic collaboration and capsid license agreement with Novartis Pharma AG, a subsidiary of Novartis AG, to advance potential gene therapies for Huntington’s disease (HD) and spinal muscular atrophy (SMA). Voyager will provide Novartis a target-exclusive license to access its TRACER capsids and other intellectual property for the respective diseases, and the companies will collaborate to advance a p...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters